Prometheus Fuels Hits Major Commercial Milestone
10.7.2025 15:00:00 CEST | Business Wire | Press Release
Prometheus Fuels (Prometheus), the company making low-cost carbon-neutral fuels from direct air capture and renewable electricity, today announced it has reached commercial readiness for its proprietary e-Fuel production system. The company’s Titan Forge Alpha prototype has successfully integrated a full-scale 50-cell Faraday Reactor validating its core technology at TRL 9, the highest benchmark for real-world deployment and system maturity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710099048/en/
Prometheus Fuels' Titan Forge Alpha prototype has successfully integrated a full-scale 50-cell Faraday Reactor validating its core technology at TRL 9, the highest benchmark for real-world deployment and system maturity. With this milestone, Prometheus becomes the only company capable of producing low-cost carbon-neutral e-Fuel using direct air capture (DAC) and intermittent renewable energy, fully off-grid.
With this milestone, Prometheus becomes the only company capable of producing low-cost carbon-neutral e-Fuel using direct air capture (DAC) and intermittent renewable energy, fully off-grid. The company also stands apart from other e-fuel producers in not needing subsidies or hydrogen. Its Titan Forge Alpha plant, the world’s first operational DAC synthetic fuel facility, is already generating e-methanol from air and solar power.
Next up: Titan Fuel Forge One, the company’s first commercial-scale fuel production system. It will use the same proven stack architecture and kick off a new era of production for Prometheus. To date, the company has pre-sold more than 11 million tons of e-Fuel to be delivered over the next decade, reflecting strong demand from global energy buyers and deep market confidence in the company’s technology.
The Faraday Reactor, a hydrocarbon electrolyzer that converts CO2 from an integrated DAC tower directly to fuel, is core to Prometheus’ system. Designed to operate on variable power inputs, the system thrives in remote, off-grid environments where wind and solar energy are abundant, unlocking low-cost, distributed fuel production at a global scale.
“This milestone marks a turning point, not just for Prometheus, but for the future of energy,” said Rob McGinnis, founder and CEO of Prometheus. “We’ve invented and built an integrated DAC and fuel synthesis system that captures carbon from the air, runs on renewable energy, and produces e-Fuels that cost less than fossil at scale. It’s the kind of innovation that doesn’t just move the needle, it resets the standard. After years of development and validation, we’re now ready to scale and meet the world’s growing demand for energy.”
As AI workloads surge and data centers multiply, demand is rising for reliable, around-the-clock clean power. Solar is now the cheapest form of energy in the world, but its full potential has been limited by challenges in capture, transport, and storage. Batteries and grid infrastructure can’t fully solve the problem — especially in remote, fast-growing, or under-connected regions.
Prometheus’ patented technology turns cheap, abundant solar power into carbon-neutral fuel that works as firm, dispatchable baseload energy. It can be stored indefinitely, delivered anywhere without new transmission lines, and used to stabilize grids, power AI and data centers, and fuel global demand for steady, low-cost clean energy.
“We knew we had to be able to beat fossil fuels on cost from the beginning and that’s what we’ve achieved,” McGinnis added. “We don’t need subsidies, we don’t need hydrogen, we don’t need biogenic point-source CO2, and we don’t need the grid. We can turn the lowest cost energy in the world from solar in the best locations into liquid fuels that can meet the fast-growing need for new power. We’re ready to scale to meet real demand.”
The company’s core technology is patent-protected and has undergone third-party technical validation in preparation for full-scale commercial deployment. To see a demo of Prometheus fuel powering the company’s 1968 Mustang Fastback, the “Promethean Stang,” visit: https://bit.ly/Promethean-Stang-Reveal. To learn more about Prometheus visit: https://prometheusfuels.com/.
About Prometheus Fuels
Prometheus is the global leader in carbon-neutral fuels made from direct air capture and renewable electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces fuel at fossil fuel prices without subsidies, transforming energy production. Designed to run off-grid, Prometheus offers a scalable source of new power, transforming intermittent renewable energy into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, Y Combinator, Paul Graham, Jaan Tallinn, John and Patrick Collison, Garrett Camp, and Tom Preston-Werner, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710099048/en/
Contacts
Media Contact:
Nickell Communications for Prometheus Fuels:
prometheus@nickellcommunications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom